Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-release carbamazepine (Equetro) for bipolar disorder

    The Medical Letter on Drugs and Therapeutics
    |March 30, 2005
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Inebilizumab (Uplizna) for myasthenia gravis.

    The Medical letter on drugs and therapeutics·2026
    Same journal

    Breztri Aerosphere for asthma.

    The Medical letter on drugs and therapeutics·2026
    Same journal

    Fosfomycin (Contepo) for complicated urinary tract infections.

    The Medical letter on drugs and therapeutics·2026
    Same journal

    Baxdrostat (Baxfendy) - an aldosterone synthase inhibitor for hypertension.

    The Medical letter on drugs and therapeutics·2026
    Same journal

    Comparison chart: Drugs for motion sickness.

    The Medical letter on drugs and therapeutics·2026
    Same journal

    In brief: Apixaban vs rivaroxaban for acute VTE.

    The Medical letter on drugs and therapeutics·2026
    See all related articles

    Equetro, an extended-release carbamazepine formulation, is approved for acute mania and mixed episodes in bipolar disorder. While effective short-term, it is not recommended for maintenance therapy and shows no superior efficacy to existing treatments like lithium or valproate.

    Area of Science:

    • Pharmacology
    • Psychiatry
    • Neurology

    Background:

    • Carbamazepine extended-release formulation approved for epilepsy since 1997.
    • New approval for Equetro (carbamazepine) targets acute mania and mixed episodes in bipolar disorder.

    Purpose of the Study:

    • To evaluate the efficacy and safety of Equetro for acute mania and mixed episodes of bipolar disorder.
    • To assess the suitability of carbamazepine for maintenance treatment in bipolar disorder.

    Main Methods:

    • Clinical trial data assessing carbamazepine's effectiveness in bipolar disorder patients.
    • Comparison of carbamazepine efficacy against established treatments like lithium and valproate.

    Main Results:

    • Equetro demonstrated effectiveness in treating acute mania and mixed episodes for up to six months.

    Related Experiment Videos

  • Carbamazepine did not prove more effective than lithium or valproate.
  • Serious adverse effects associated with carbamazepine use were noted.

    • Conclusions:

    • Equetro is a viable option for short-term treatment of acute mania and mixed episodes in bipolar disorder.
    • Carbamazepine is not indicated for maintenance therapy in bipolar disorder.
    • Clinicians should weigh the potential serious adverse effects against the benefits of carbamazepine compared to other mood stabilizers.